

# **Th 17 and T reg cells in type 2 diabetic nephropathy**

**Thesis**

**Submitted for partial fulfillment of Master degree in  
internal medicine**

**By**

**Mohamed Ashraf Ibrahim**

**M.B. B. Ch.**

**Cairo University**

**Supervised by**

**Prof. Dr. Ashraf Mahmoud Okba**

**Professor of Allergy, Clinical Immunology and Internal  
Medicine**

**Faculty of Medicine, Ain Shams University**

**Dr. Abeer Abdelhamid Eissa**

**Lecturer of Allergy, Clinical Immunology and Internal  
Medicine**

**Faculty of Medicine, Ain Shams University**

**Dr. Malak Nabil Amin**

**Lecturer of Internal Medicine and Nephrology  
Theodor Bilharz Research Institute**

**Faculty of Medicine  
Ain Shams University**

**2015**

## ACKNOWLEDGEMENT

First of all thanks to **ALLAH** for providing me with time and effort to accomplish this thesis.

I would like to express my sincerest appreciation and gratitude to Professor Dr. **Ashraf Mahmoud Okba**, for suggesting the subject, his great effort, his continuous encouragement, advice and guidance to get this work to its final form. It was a privilege to be under his supervision in this thesis.

I wish to express my deep gratitude to Dr. **Abeer Abdelhamid Eissa**, for her enthusiasm, keen supervision, continuous encouragement and meticulous guidance and follow up throughout this work.

A special tribute and cordial thanks are paired to Dr. **Malak Nabil Amin**, for her authentic guidance and meticulous supervision. She gave me a lot of her time, effort and experience to accomplish this work.

Last but not least, I would like to thank my parents, my family and my colleagues for all their patience, love and support which made this work possible.

My great gratitude goes to my dear wife, the one who really cares.

# **TABLE OF CONTENTS**

	<b>Page N.</b>
List of tables	III
List of figures	V
List of abbreviations	IX
Introduction	1
Aim of work	3
Chapter 1: Diabetes Mellitus	4
Chapter 2: Diabetic nephropathy	18
Chapter 3:T cells subsets and T cell mediated immunity	46
Chapter 4: T regulatory cells	63
Chapter 5: T helper 17 cells	74
Subjects and Methods	87
Results	98
Discussion	125
Summary and Conclusions	138
Recommendations	140
References	141
Arabic summary	

## **LIST OF TABLES**

<b>Table A</b>	Etiologic classification of diabetes mellitus	5
<b>Table B</b>	Stages of Chronic Kidney Disease	42
<b>Table 1</b>	Comparison of the three study groups: Gender	98
<b>Table 2</b>	Comparison of the three study groups: Age	99
<b>Table 3</b>	Comparison of the three study groups: Hypertension and IHD.	99
<b>Table 4</b>	Comparison of the three study groups: Duration of diabetes and Duration of hypertension	100
<b>Table 5</b>	Comparison of the three study groups: FBS, PPBS and HbA1c%	101
<b>Table 6</b>	Comparison of the three study groups: Albuminuria.	101
<b>Table 7</b>	Comparison of the three study groups: Total cholesterol, LDL, HDL and TAG	102
<b>Table 8</b>	Comparison of the three study groups: statins	102
<b>Table 9</b>	Comparison of the three study groups: Th 17, T reg and Th 17/T reg	103
<b>Table 10</b>	Correlation between Th17, Treg, and	106

## List of Tables

	Th17/Treg ratio and lipids (Total cholesterol, LDL, HDL and TAG) in diabetic patients	
<b>Table 11</b>	Correlation between Th17, Treg, and Th17/Treg ratio and BUN, serum creatinine, creatinine clearance and proteinuria in diabetic patients	107
<b>Table 12</b>	Correlation between Th17, Treg, and Th/Treg ratio and the grade of nephropathic affection by ultrasound in the whole study population	114
<b>Table 13</b>	Relation between Th17, Treg, and Th/Treg ratio and hypertension in the whole study population; controls and diabetic patients	116
<b>Table 14</b>	Receiver-operating characteristic curve analysis for the value of Th17 in classification of diabetic patients into those with or without nephropathy	119
<b>Table 15</b>	Receiver-operating characteristic curve analysis for the value of Treg in classification of diabetic patients into those with or without nephropathy	121
<b>Table 16</b>	Receiver-operating characteristic curve analysis for the value of Th17/Treg ratio in classification of diabetic patients into those with or without nephropathy	123

## **LIST OF FIGURES**

<b>Figure (A)</b>	Possible sequence of hemodynamic events leading to onset of diabetic glomerulopathy	21
<b>Figure (B)</b>	Schematic representation of stretch mechanisms	23
<b>Figure (C)</b>	Mechanisms of dyslipidemia in diabetic nephropathy	33
<b>Figure (D)</b>	Development of t cell-mediated responses is a sequential process	49
<b>Figure (E)</b>	Differentiation of effector t cells	52
<b>Figure (F)</b>	Cytotoxic T Lymphocyte cytotoxicity can be mediated By two distinct pathways	58
<b>Figure (G)</b>	Several mechanisms mediate t reg cell function	67
<b>Figure (H)</b>	Functionally distinct Th17 cell subsets are induced by different cytokines	78
<b>Figure (I)</b>	The homeostasis of Treg and Th17 cells	80
<b>Figure (1)</b>	Mean Th17 in the three study groups. Error bars represent 95% CI	104
<b>Figure (2)</b>	Mean Treg in the three study groups. Error bars represent 95% CI	104
<b>Figure (3)</b>	Mean Th17/ Treg ratio in the three study groups. Error bars represent 95% CI.	105
<b>Figure (4)</b>	Scatter plot for the correlation between Th17 and BUN in controls and diabetics. Plotted lines represent local regression smoothing (LOESS) trend lines	108

## List of Figures

<b>Figure (5)</b>	Scatter plot for the correlation between Th17 and serum creatinine in controls and diabetics. Plotted lines represent local regression smoothing (LOESS) trend lines.	108
<b>Figure (6)</b>	Scatter plot for the correlation between Th17 and creatinine clearance in diabetics. Plotted line represents local regression smoothing (LOESS) trend line	109
<b>Figure (7)</b>	Scatter plot for the correlation between Th17 and proteinuria in diabetics. Plotted line represents local regression smoothing (LOESS) trend line	109
<b>Figure (8)</b>	Scatter plot for the correlation between Treg and BUN in controls and diabetics. Plotted lines represent local regression smoothing (LOESS) trend lines	110
<b>Figure (9)</b>	Scatter plot for the correlation between Treg and serum creatinine in controls and diabetics. Plotted lines represent local regression smoothing (LOESS) trend lines	110
<b>Figure (10)</b>	Scatter plot for the correlation between Treg and creatinine clearance in diabetics. Plotted line represents local regression smoothing (LOESS) trend line	111
<b>Figure (11)</b>	Scatter plot for the correlation between Treg and proteinuria in diabetics. Plotted line represents local regression smoothing (LOESS) trend line	111
<b>Figure (12)</b>	Scatter plot for the correlation between Th17/Treg ratio and BUN in controls and diabetics. Plotted lines represent local regression smoothing (LOESS) trend lines.	112
<b>Figure (13)</b>	Scatter plot for the correlation between Th17/Treg ratio and serum creatinine in controls and diabetics.	112

## List of Figures

	Plotted lines represent local regression smoothing (LOESS) trend lines	
<b>Figure (14)</b>	Scatter plot for the correlation between Th17/Treg ratio and creatinine clearance in diabetics. Plotted line represents local regression smoothing (LOESS) trend line	113
<b>Figure (15)</b>	Scatter plot for the correlation between Th17/Treg ratio and proteinuria in diabetics. Plotted line represents local regression smoothing (LOESS) trend line	113
<b>Figure (16)</b>	Scatter plot for the correlation between Th17 and the grade of nephropathy by US in the whole study population. Plotted lines represent local regression smoothing (LOESS) trend lines.	114
<b>Figure (17)</b>	Scatter plot for the correlation between Treg and the grade of nephropathy by US in the whole study population. Plotted lines represent local regression smoothing (LOESS) trend lines.	115
<b>Figure (18)</b>	Scatter plot for the correlation between the Th17/Treg ratio and the grade of nephropathy by US in the whole study population. Plotted lines represent local regression smoothing (LOESS) trend lines.	115
<b>Figure (19)</b>	Mean Th17 in patients with or without hypertension. Error bars represent 95% CI.	117
<b>Figure (20)</b>	Mean Treg in patients with or without hypertension. Error bars represent 95% CI	117
<b>Figure (21)</b>	Mean Th17/Treg ratio in patients with or without hypertension. Error bars represent 95% CI	118
<b>Figure (22)</b>	Receiver-operating characteristic curve for the value of Th17 in classification of diabetic patients into	120



## List of Figures

---

	those with or without nephropathy	
<b>Figure (23)</b>	Receiver-operating characteristic curve for the value of Treg in classification of diabetic patients into those with or without nephropathy	122
<b>Figure (24)</b>	Receiver-operating characteristic curve for the value of Th17/Treg ratio in classification of diabetic patients into those with or without nephropathy	124

## **LIST OF ABBREVIATIONS**

<b>Abbreviation</b>	<b>Full term</b>
<b>(2hPP)</b>	2 hour post prandial
<b>(3-DG)</b>	3 Deoxyglucosone
<b>(A II)</b>	Angiotensin 2
<b>(Ab)</b>	antibody
<b>(ACE)</b>	Angiotensin converting enzyme
<b>(ACORD)</b>	Anemia correction in diabetes
<b>(ACR)</b>	Albumin creatinine ratio
<b>(ADA)</b>	American diabetes association
<b>(ADP)</b>	Adenosine di-phosphate
<b>(AER)</b>	Albumin excretion rate
<b>(Ag)</b>	Antigen
<b>(AGEs)</b>	Advanced glycated end products
<b>(Ala)</b>	Alanine
<b>(ALT)</b>	Alanine transaminase
<b>(AMP)</b>	Adenosine mono-phosphate
<b>(APC)</b>	Antigen presenting cells
<b>(Apo E)</b>	Apolipoprotein E

## List of Abbreviations

---

<b>(AR)</b>	Aldose reductase
<b>(ARB)</b>	Angiotensin 2 receptor blocker
<b>(AST)</b>	Aspartate transaminase
<b>(ATP)</b>	Adenosine tri-phosphate
<b>(B1)</b>	Bradykinin receptor 1
<b>(B2)</b>	Bradykinin receptor 2
<b>(Ca<sup>+2</sup>)</b>	Calcium
<b>(c-AMP)</b>	Cyclic adenosine monophosphate
<b>(CBC)</b>	Complete blood count
<b>(CBF-B)</b>	Core binding factor beta
<b>(CCR-3)</b>	Chemokine receptor 3
<b>(CCR-4)</b>	Chemokine receptor 4
<b>(CCR-5)</b>	Chemokine receptor 5
<b>(CCR-6)</b>	Chemokine receptor 6
<b>(CCR-7)</b>	Chemokine receptor 7
<b>(CD)</b>	Cluster of differentiation
<b>(CKD)</b>	Chronic kidney disease
<b>(cTECs)</b>	Cortical thymic epithelial cells
<b>(CTGF)</b>	Connective tissue growth factor
<b>(CTL)</b>	Cytotoxic T lymphocyte

## List of Abbreviations

---

<b>(CTLA-4)</b>	Cytotoxic T lymphocyte antigen 4
<b>(CVA)</b>	Cerebrovascular accident
<b>(CXCL-2)</b>	Chemokine 2
<b>(CXCL-8)</b>	Chemokine 8
<b>(DC)</b>	Dendritic cells
<b>(DKD)</b>	Diabetic kidney disease
<b>(DM)</b>	Diabetes Mellitus
<b>(DN)</b>	Diabetic Nephropathy
<b>(DNA)</b>	Deoxyribonucleic acid
<b>(DTH)</b>	Delayed type hypersensitivity
<b>(EDTA)</b>	Ethylene diamine tetra acetic acid
<b>(eGFR)</b>	Estimated glomerular filtration rate
<b>(ESRD)</b>	End stage renal disease
<b>(FBS)</b>	Fasting blood sugar
<b>(FITC)</b>	Fluorescein isothiocyanate stain
<b>(FOX P<sub>3</sub>)</b>	Forked-winged helix transcription factor
<b>(FPG)</b>	Fasting plasma glucose
<b>(GBM)</b>	Glomerular basement membrane
<b>(GDM)</b>	Gestational diabetes mellitus

## List of Abbreviations

---

<b>(GFR)</b>	Glomerular filtration rate
<b>(GHbs)</b>	Glycated hemoglobin
<b>(GLUT-1)</b>	Glucose transporter 1
<b>(GM-CSF)</b>	Granulocyte macrophage colony stimulating factor
<b>(Hb)</b>	Hemoglobin
<b>(HbA1c)</b>	Glycated Hemoglobin
<b>(HDL)</b>	High density lipoprotein
<b>(HMC)</b>	Human mesangial cells
<b>(HNF)</b>	Hepatocyte nuclear factor
<b>(i T reg)</b>	Inducible T regulatory cells
<b>(ICOS)</b>	Inducible T cell co stimulation
<b>(IFN- <math>\gamma</math>)</b>	Interferon gamma
<b>(Ig A)</b>	Immunoglobulin A
<b>(Ig E)</b>	Immunoglobulin E
<b>(Ig G)</b>	Immunoglobulin G
<b>(Ig)</b>	immunoglobulin
<b>(IGF-1)</b>	Insulin like growth factor 1
<b>(IGFs)</b>	Insulin like growth factors
<b>(IHD)</b>	Ischemic heart disease

## List of Abbreviations

---

<b>(IL)</b>	Interleukin
<b>(IL-12R<math>\beta</math>1)</b>	interleukin -12 receptor beta 1
<b>(IL-22R)</b>	interleukin -22 receptor
<b>(IL-23R)</b>	interleukin-23 receptor
<b>(IL-2R)</b>	Interleukin 2 receptor
<b>(IPF-1)</b>	Insulin promoter factor 1
<b>(IRF4)</b>	interferon regulatory factor 4
<b>(K<sup>+</sup>)</b>	Potassium
<b>(LDL)</b>	low density lipoprotein
<b>(LFA-1)</b>	Leukocyte function antigen 1
<b>(LPL)</b>	Lipoprotein lipase
<b>(m RNA)</b>	Messenger ribonucleic acid
<b>(MCH)</b>	Mean corpuscular hemoglobin
<b>(MCHC)</b>	Mean corpuscular hemoglobin concentration
<b>(MCV)</b>	Mean corpuscular volume
<b>(MHC)</b>	major histocompatibility complex
<b>(MODY)</b>	Maturity onset diabetes of young
<b>(mTECs)</b>	Medullary thymic epithelial cells
<b>(MTHFR)</b>	Methylene tetrahydrofolate reductase
<b>(Na<sup>+</sup>)</b>	Sodium

## List of Abbreviations

---

<b>(NADPH)</b>	Nicotinamide Adenine Dinucleotide Phosphate Hydrogen
<b>(NIDDM)</b>	Non insulin dependant diabetes mellitus
<b>(NK )</b>	Natural killer cells
<b>(NKT)</b>	Natural killer T-cells
<b>(nT regs)</b>	Natural T regulatory cells
<b>(OGTT)</b>	Oral glucose tolerance test
<b>(OPG)</b>	Osteoprotegerin
<b>(P38MAPK)</b>	P38 mitogen activated protein kinase
<b>(PBS)</b>	Phosphate buffered saline
<b>(PC)</b>	Phycoerythrin cyanine stain
<b>(PD-1)</b>	Programmed death 1
<b>(PDGF)</b>	Platelet derived growth factor
<b>(PE)</b>	Phycoerythrin stain
<b>(PFN)</b>	Perforin
<b>(PKC)</b>	Protein kinase C
<b>(PLT)</b>	Platelets
<b>(P-MHC)</b>	Peptide major histocompatibility complex
<b>(PPAR→)</b>	peroxisome proliferators-activated receptors →
<b>(RAGE)</b>	Receptor for advanced glycation end product